UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diagnostic Utility of Inflammatory Markers as Early Predictor of Anastomotic Leak after Elective Colectomy

Journal of the American College of Surgeons, 2020-10, Vol.231 (4), p.e9-e10

2020

Volltextzugriff (PDF)

Robot‐assisted radical prostatectomy in Aotearoa New Zealand: equity, quality, and workforce

ANZ journal of surgery, 2023-12, Vol.93 (12), p.2789-2791

2023

Volltextzugriff (PDF)

Defining the Physiological Inflammatory Response after Elective Colonic Surgery

Journal of the American College of Surgeons, 2020-10, Vol.231 (4), p.e95-e96

2020

Volltextzugriff (PDF)

Evidence-Based Management of Postoperative Pain in Adults Undergoing Laparoscopic Sleeve Gastrectomy

World journal of surgery, 2019-06, Vol.43 (6), p.1571-1580

2019

Volltextzugriff (PDF)

Effectiveness of Standardized Clerkship Teaching Across Multiple Sites

The Journal of surgical research, 2011-06, Vol.168 (1), p.e17-e23

2011

Volltextzugriff (PDF)

Topical vs Oral Metronidazole after Excisional Hemorrhoidectomy: A Prospective, Double-Blind Randomized Controlled Trial

Journal of the American College of Surgeons, 2020-10, Vol.231 (4), p.S71

2020

Volltextzugriff (PDF)

Perioperative Infusions of Intravenous Lidocaine Compared with Intraperitoneal Lidocaine in Laparoscopic Colon Operations: A Randomized Clinical Trial

Journal of the American College of Surgeons, 2020-10, Vol.231 (4), p.S63-S64

2020

Volltextzugriff (PDF)

Short and long-term impact of sarcopenia on outcomes from emergency laparotomy

European journal of trauma and emergency surgery (Munich : 2007), 2022-10, Vol.48 (5), p.3869-3878

2022

Volltextzugriff (PDF)

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14597-e14597

2023

Volltextzugriff (PDF)

Systematic Review of Quality Improvement Processes, Interventions and Structure in Surgery, Obstetric, Trauma, and Anesthesia Systems in Low- and Middle-Income Countries

Journal of the American College of Surgeons, 2020-10, Vol.231 (4), p.S130-S131

2020

Volltextzugriff (PDF)

Routine Neurectomy of Inguinal Nerves During Open Onlay Mesh Hernia Repair: A Meta-analysis of Randomized Trials

Annals of surgery, 2016-07, Vol.264 (1), p.64-72

2016

Volltextzugriff (PDF)

Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9506-9506

2024

Volltextzugriff (PDF)

Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9542-9542

2023

Volltextzugriff (PDF)

A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9593-TPS9593

2022

Volltextzugriff (PDF)

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9522-9522

2022

Volltextzugriff (PDF)

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3510-3510

2022

Volltextzugriff (PDF)

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9506-9506

2021

Volltextzugriff (PDF)

Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.445-445

2018

Volltextzugriff (PDF)

Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9514-9514

2019

Volltextzugriff (PDF)

Media portrayal of Māori and bariatric surgery in Aotearoa/New Zealand

New Zealand medical journal, 2018-07, Vol.131 (1479), p.72-80

Rahiri, Jamie-Lee

2018

Volltextzugriff (PDF)

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3531-3531

2017

Volltextzugriff (PDF)

Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.578-578

2014

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9506-9506

2016

Volltextzugriff (PDF)

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)

Journal of clinical oncology, 2015-06, Vol.33 (18_suppl), p.LBA1-LBA1

2015

Volltextzugriff (PDF)

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.LBA1-LBA1

2015

Volltextzugriff (PDF)

1 – 25 von 237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(218)
Mit Volltextzugriff
(194)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Diagnostic Utility of Inflammatory Markers as Early Predictor of Anastomotic Leak after Elective Colectomy

Robot‐assisted radical prostatectomy in Aotearoa New Zealand: equity, quality, and workforce

Defining the Physiological Inflammatory Response after Elective Colonic Surgery

Evidence-Based Management of Postoperative Pain in Adults Undergoing Laparoscopic Sleeve Gastrectomy

Effectiveness of Standardized Clerkship Teaching Across Multiple Sites

Topical vs Oral Metronidazole after Excisional Hemorrhoidectomy: A Prospective, Double-Blind Randomized Controlled Trial

Perioperative Infusions of Intravenous Lidocaine Compared with Intraperitoneal Lidocaine in Laparoscopic Colon Operations: A Randomized Clinical Trial

Short and long-term impact of sarcopenia on outcomes from emergency laparotomy

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation

Systematic Review of Quality Improvement Processes, Interventions and Structure in Surgery, Obstetric, Trauma, and Anesthesia Systems in Low- and Middle-Income Countries

Routine Neurectomy of Inguinal Nerves During Open Onlay Mesh Hernia Repair: A Meta-analysis of Randomized Trials

Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study

Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067

A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS)

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma

Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody

Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C

Media portrayal of Māori and bariatric surgery in Aotearoa/New Zealand

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study

Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)

Suchergebnisse filtern